Targovax ASA: Invitation to second quarter and first half 2017 results presentation Thursday 24 August
Oslo, Norway, 14 August 2017 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, will announce its second quarter and first half 2017 results on Thursday, 24 August 2017. A presentation by Targovax's management to investors, analysts and the press will take place in Oslo at 10:00 CET.
The results report and the presentation will be available at www.targovax.com in the Investors section from 07:00 CET.
The presentation will take place at 10:00 CET at:
The presentation will also be webcast live and can be accessed through www.targovax.com.
At 14:00 CET (08:00 EST) the company will host a telephone conference which will include a presentation of the results, followed by a Q&A session. Targovax's management will present the Company. Call-in details can be found below.
Norway Toll-Free Number: 800 19 747
Norway Toll Number: +47 2350 0559
UK Toll-Free Number: 08082370030
UK Toll Number: +44 2031394830
US Toll-Free Number: 1 866 928 7517
US Toll Number: +1 718 873 9077
Access code: 32191771#
Please make sure to dial in at least 5-10 minutes ahead to complete your registration.
See attached list for more dial-in numbers.
For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Media and IR enquires:
Jan Petter Stiff - Crux Advisers (Norway)
Phone: +47 995 13 891
Julia Phillips/Simon Conway - FTI Consulting (International)
Phone: +44 20 3727 1000
Arming the patient's immune system to fight cancer
Targovax is a clinical stage company focused on developing and commercializing novel immuno-oncology therapies to target, primarily, treatment-resistant solid tumors. Immuno-oncology is currently one of the fastest growing therapeutic fields in medicine.
The Company's development pipeline is based on two novel proprietary platforms:
The first platform, ONCOS, uses oncolytic viruses, an emerging class of biological therapy. ONCOS exclusively uses an adenovirus that has been engineered to be an immune activator that selectively target cancer cells. In phase I it has shown to immune activate at lesional level which was associated with clinical benefit. In an ongoing phase I trial in advanced melanoma we expect important proof of concept data for checkpoint inhibitor refractory patients.
The second platform, TG peptides (TG), solely targets tumors that express mutated forms of the RAS protein. Mutations to this protein are common in many cancers and are known to drive aggressive disease progression and treatment resistance. There is a high unmet medical need for therapies that are effective against tumors that express these mutations. The TG platform's therapeutic potential stems from its ability to enable a patient's immune system to identify and then destroy tumors bearing any RAS mutations. In early 2017, key proof of concept data for the TG platform from a clinical trial of TG01 in resected pancreatic cancer patients showed encouraging overall survival and will give guidance for the future clinical development of this platform.
Targovax's development pipeline has three novel therapeutic candidates in clinical development covering six indications.
Both platforms are protected by an extensive portfolio of IP and know-how and have the potential to yield multiple product candidates in a cost-effective manner. Additionally, Targovax has other products in early stages of development.
In July 2016, the Company listed its shares on Oslo Axess. In March 2017, the shares were upgraded to Oslo Børs, the main Oslo Stock Exchange.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.